- Home
- ONEG vs ELTX Comparison
ONEG vs ELTX Comparison
Compare ONEG & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEG | ELTX |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 141.3M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | ONEG | ELTX |
|---|---|---|
| Price | $1.23 | $7.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 116.0K | 103.1K |
| Earning Date | 02-16-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $53,205,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $4.60 |
| 52 Week High | $13.50 | $12.62 |
Technical Indicators
Market Signals| Indicator | ONEG | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.10 | 43.63 |
| Support Level | $1.08 | $7.89 |
| Resistance Level | $1.27 | $8.32 |
| Average True Range (ATR) | 0.13 | 0.42 |
| MACD | 0.32 | 0.03 |
| Stochastic Oscillator | 53.57 | 21.33 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.